<DOC>
	<DOC>NCT01440920</DOC>
	<brief_summary>The purpose of this study is to assess the safety, tolerability of OCV-501 in patients with acute myeloid leukemia (AML) who achieved complete remission after induction regimen and who completed a standard consolidation therapy.</brief_summary>
	<brief_title>A Phase I Study of OCV-501 in Acute Myeloid Leukemia Patients</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<criteria>Key Patients with acute myeloid leukemia including patients with secondary leukemia. However, the patients with MDS apparently evolved itno AML and patients with AML accompanied by t(15;17)(q22;q12),(PML/RARalpha) , should be excluded. Patients who achieved the first complete remission after the induction regimen and finished a standard consolidation therapy. Age: â‰¥ 60years of age(at the time of signature of the informed consent form) Sex: Male and Female Patients who are capable of giving informed consent Patient's blasts cells show expression of WT1mRNA, detected by quantitative RTPCR. Patients must be one of the following HLA DRB1 types: HLADRB1*01:01, *04:05, *15:01, *15:02, *08:03 and *09:01. Key Patients who are scheduled for a bone marrow transplantation Patients who were administered exceeded acceptable therapeutic dose of immunosuppressants and adrenal cortical steroids. Patients with uncontrollable active infectious diseases Patients with autoimmune diseases (including Hashimoto's disease, idiopathic thrombocytopenic purpura, and autoimmune hepatitis) or with a medical history of active autoimmune diseases Immunocompetent patients Patients with a complication of interstitial pneumonia or with a medical history of interstitial pneumonia</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>WT1</keyword>
</DOC>